Results 311 to 320 of about 9,044,537 (408)
Clustering Algorithm Reveals Dopamine‐Motor Mismatch in Cognitively Preserved Parkinson's Disease
ABSTRACT Objective To explore the relationship between dopaminergic denervation and motor impairment in two de novo Parkinson's disease (PD) cohorts. Methods n = 249 PD patients from Parkinson's Progression Markers Initiative (PPMI) and n = 84 from an external clinical cohort.
Rachele Malito +14 more
wiley +1 more source
Comparative evaluation of five tacrolimus assays in transplant recipients: implications for optimizing therapeutic drug monitoring. [PDF]
SahBandar IN +8 more
europepmc +1 more source
Neuroinflammation in GAD65 Antibody‐Associated Epilepsy Measured Using [18F]DPA‐714 PET/MRI
ABSTRACT The timing for initiating immunotherapy in patients with glutamic acid decarboxylase 65 (GAD65) antibody‐associated epilepsy is a challenge. We used the translocator protein radioligand [18F]DPA‐714 and PET to evaluate brain microglial activation.
Jingjing Chen +10 more
wiley +1 more source
Monitoring biosafety of pharmaceutical drugs, insecticides, and other bioactive molecules to mitochondria [PDF]
S. Akbar, K. Sreeramulu, HL Sharma
openalex
Functional and Structural Evidence of Neurofluid Circuit Aberrations in Huntington Disease
ABSTRACT Objective Disrupted neurofluid regulation may contribute to neurodegeneration in Huntington disease (HD). Because neurofluid pathways influence waste clearance, inflammation, and the distribution of central nervous system (CNS)–delivered therapeutics, understanding their dysfunction is increasingly important as targeted treatments emerge.
Kilian Hett +8 more
wiley +1 more source
Therapeutic Drug Monitoring of Psychotropic Drugs in Inpatient Psychiatry: Local Practice and Improvement. [PDF]
Pfeifer P +6 more
europepmc +1 more source
Therapeutic Drugs Monitoring and the Consequences for Health and Well-Being
O. O. Edenya, K. Atoe
openalex +2 more sources
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang +4 more
wiley +1 more source

